pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 38 Non-oncology: 21
Oncology: 17
Under Consideration for Negotiation 32 Non-oncology: 21
Oncology: 11
Completed Negotiations 595 With Letter of Intent: 509
Without agreement: 86
Negotiations That Were Not Pursued 97

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Lorbrena Pfizer Canada ULC for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Radicava Mitsubishi Tanabe Pharma Canada, Inc. amyotrophic lateral sclerosis
Verzenio Eli Lilly Canada Inc. in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based o
Tepmetko EMD Serono Canada, a division of EMD Inc. For the treatment of adult patients with locally advanced unresectable metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations
Beovu Novartis Pharmaceuticals Canada Inc. Diabetic Macular Edema

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Vegzelma Celltrion Healthcare Canada Ltd. For the treatment of: Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recu
Rozlytrek HOFFMANN-LA ROCHE LIMITED For the treatment of adult patients with unresectable locally advanced or metastatic extracranial solid tumours, including brain metastases, that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
Tecentriq Hoffmann-La Roche Indicated as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition) non-small cell lung cancer (NSCLC) whose tumours
Dojolvi Ultragenyx Canada Inc. long-chain fatty acid oxidation disorders
Nypozi Tanvex BioPharma USA, Inc. Prevention or treatment of neutropenia in various indications
Dupixent sanofi-aventis Canada Inc. Asthma
Trodelvy Gilead Sciences Canada Inc. For the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior therapies, at least one of them for metastatic disease
Scemblix Novartis Pharmaceuticals Canada Inc. For the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with two or more tyrosine kinase inhibitors
Keytruda Merck Canada Inc. for the treatment of adult patients with persistent, recurrent, or metastatic cervical cancer whose tumours express PD‐L1 (CPS ≥ 1) as determined by a validated test, in combination with chemotherapy with or without bevacizumab
Keytruda Merck Canada Inc. For the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternati
Keytruda Merck Canada Inc. Pembrolizumab in combination with chemotherapy, for the treatment of adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC), who have not received prior chemotherapy for metastatic disease and whose tumors ex
Keytruda Merck Canada Inc. for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection
Sarclisa Sanofi Genzyme In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
Sarclisa Sanofi Genzyme Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
Piqray Novartis Pharmaceuticals Canada Inc. In combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regi

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
Ozurdex AbbVie Corporation Diabetic Macular Edema